Given the increasing use of GLP-1 RAs in post-bariatric patients, it is also recommended to monitor emergency visits related to gastrointestinal symptoms (e.g., epigastric pain, nausea, vomiting — potentially suggesting paralytic ileus —) or local adverse reactions (e.g., hematomas, infection, or bleeding at the injection site). The gene discussed is GCG; the disease is Paralytic ileus.